ISSN: 2329-9053

Journal of Molecular Pharmaceutics & Organic Process Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Journals Readership Metrics (Source: Google Analytics)

The Journal of Molecular Pharmaceutics & Organic Process Research is an Open Access journal that aims to publish most complete and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications etc in all areas of study of the Biochemistry, Pharmaceutical-analysis, and Drug delivery, as well as the Molecular pharmaceutics. This is a great platform for the authors to make their contribution towards the journal and the editorial office promises a peer review process for the submitted manuscripts for the quality of publishing.

Google Analytics has revealed an amazing statistics regarding the popularity of this journal. All through Jan 2013-Aug 2022 there were 24,875 page views. The total number of returning visitors were about 6,020. Moreover, globally 18,855+ new users have accessed the journal website for information on the journal and the published articles.

Google Analytics Metrics: At Glimpse

A statistical representation of global users for Journal of Molecular Pharmaceutics & Organic Process Research (Source: Google Analytics)

Visitor Analysis Report

More than 15,000+ Visitors visiting the journal site to read the published articles or submit their research outcomes Highest number of Visitors reporting both from the developed and developing nations Majority of the visitors have come from USA (10.95%), India (20.43%), United Kingdom (1.64%), Indonesia (3.65%), Turkey (3.64%) and Phillippines (2.05%) The Journal received tremendous attention from the researchers in terms of visits from Manchester, New Delhi, Brussels, Seoul, Tokyo, Addid Ababa etc. The observed percentage of new sessions recorded is 61.61%. The average Time spent by the visitor for each session is 3.14 Minute.

Reasons for enlisting Journal of Molecular Pharmaceutics & Organic Process Research Informatics on top of search engines: (Source: Google)

Global Internet users for omicsonline.org Statistical representation (Source: Google Analytics)

A statistical Analysis on global internet users of omicsonline.org (By Google Analytics)

Visitor Analysis Report

Journals published OMICS International is frequently receiving responses from the authors and readers globally. Multiple journals published in various subjects including Medical, Pharma, Engineering, Sciences, Technology and Business attracting more than 14,026,825 users with more than 44,743, 084 page views. The observed analytics values are sufficient to quantifyour journals popularity among the scientific community. Moreover, our authors and Editors profiles are also receiving tremendous visibility from their fellow colleagues through our online portals and getting recognition worldwide.

OMICS International Web Metrics

  • 58,568,720 + users
  • 158,885,500 + page views

Our journals have received 82,280,989 + sessions so far with a rate of 71.18% of new sessions which confirms the outstanding pool of new users and visitors for OMICS International journals. Open Access publishing is model has become the best choice for the authors worldwide. Due to fast and constructive peer review process, avoiding unnecessary time delay in production, and incredible ever growing visibility of the published article along with branding and promotional activity revolutionized the publishing system. OMICS journals are serving as one of the pioneer publishing medium in this context.

Top